Stock of the Day: Hims & Hers plunges 27% after saying it will stop selling its Ozempic competitor
With Hims & Hers' main source of growth set to be extinguished, Citi analysts said its full-year guidance appeared ...
ConsumerAffairs18h
Hims & Hers withdraws from Wegovy, Ozempic market
Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...
Why Hims & Hers (HIMS) Stock Is Tumbling
Hims & Hers (HIMS) stock is sinking 20% today after Eli Lilly (LLY) unveiled significantly cheaper versions of its popular ...
wtvr21h
Hims and Hers likely to stop selling cheaper versions of GLP-1 medications
The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...
Eli Lilly cuts price of weight-loss drug Zepbound as competition heats up
Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity ...
Hims & Hers shares plunge as looming curbs on drug compounding cloud forecast
Hims & Hers Health shares were headed for their biggest single-day plunge as Wall Street analysts questioned the telehealth ...
Hosted on MSN1d
Hims & Hers Stock Sinks After-Hours As Weight-Loss Roadmap Gets Clouded — Retail Pounces On The Dip
Hims & Hers Health Inc. shares plunged over 18% in after-hours trading on Monday after the telehealth company reported strong ...
Modern Healthcare1d
Hims & Hers pivots as semaglutide shortage ends
Hims & Hers co-founder and CEO Andrew Dudum said the company will pivot and focus on different offerings such as its ...